Nodality, Inc. Appoints Michael Goldberg as Executive Chairman of the Board of Directors
South San Francisco, California, June 1, 2011Nodality, Inc., a privately-held biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling (SCNP) technology platform, announced today that it has appointed Michael Goldberg as Executive Chairman of its Board of Directors.
During a career spanning 30 years, Michael Goldberg has been a company founder, CEO, board member and venture capitalist. Michael joined the life science industry in 1981 and participated in the commercialization of the first generation of recombinant DNA, monoclonal antibody and PCR. Michael joined Nodality's board to help guide the commercialization of SCNP, which he thinks has similar disruptive potential for drug development and clinical medicine. Michael has previously served as a member of the board of directors of Genomic Health (Nasdaq: GHDX), Crescendo Bioscience (Chairman), XDx (Chairman) and CardioDX. Michael was also previously founder and CEO of On Care, Inc. and Axion, Inc., and began his career as an executive with Cetus Corp. In addition to his work as a corporate board member and investor, Michael has served on the Board of the California Institute for Regenerative Medicine since its inception in 2005 ($3 billion state stem cell agency). Michael is also on the advisory councils of the Harvard Center for Genetics and Genomics, the Stanford Neuroscience Institute, the Caltech Division of Biology, and the Berkeley Center for Law and Technology. He is a member of the Personalized Medicine Coalition and an honorary trustee of the National Childhood Cancer Foundation. Michael is a former board member of the Western Association of Venture Capitalists. Michael holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.
About NodalityNodality is a private, South San Francisco-based biotechnology company focused on improving the development and clinical use of therapeutics in cancer and autoimmune disease through the application of its proprietary Single Cell Network Profiling technology platform. Through its ability to functionally characterize cell signaling networks at the single cell level of resolution Nodality is committed to the biological characterization of individual patients to optimally match them with biologically-targeted treatments.
About Single Cell Network ProfilingSingle Cell Network Profiling (SCNP) is a proprietary technology licensed from Stanford University to characterize cell signalling networks in patients with cancer and autoimmune diseases. SCNP, by measuring functional signaling network behavior in single cells, has several advantages over other currently used molecular technologies. These include unprecedented insight into the presence and clinical meaning of cellular heterogeneity including the importance of rare cells such as drug-resistant and stem cells. As the technology has widespread application in both preclinical and clinical drug development, Nodality is also utilizing SCNP in collaboration with drug developers to decrease the time, cost, and risks of drug development.